Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

THE TRUTH ABOUT: Rinvoq | History Defined

AbbVie Stock: Analyst Estimates & Ratings

After Humira’s patent cliff, what do analysts think about AbbVie’s stock now?

2 Dividend Kings Quietly Beating the Market This Year

2 Dividend Kings Quietly Beating the Market This Year

These two are the calm outperformers that might have been overlooked.

Should You Buy This Blue-Chip Dividend Stock at Record Highs?

Should You Buy This Blue-Chip Dividend Stock at Record Highs?

AbbVie shares have hit record highs after extending Rinvoq’s patent protection to 2037, boosting confidence in future earnings and dividend growth, with analysts seeing steady fundamentals and modest upside as the company’s immunology pipeline drives results.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

AbbVie Soars On Skyrizi And Rinvoq Strength, Outpacing Humira Erosion

On Thursday, AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 billion.

AbbVie Stock Eyes Breakout as Pipeline and Profits Grow

AbbVie stock pops after strong Q2 earnings and raised guidance, as Skyrizi and Rinvoq offset Humira's decline and support a bullish outlook

Is Wall Street Bullish or Bearish on AbbVie Stock?

Despite AbbVie's underperformance relative to the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock's future.

AbbVie Investors Trigger Trend-Following Signal: Time to Load Up

AbbVie is on track to sustain growth in the wake of Humira's patent cliff and the forecasts are too low. Investors can look forward to an upgrade cycle in 2025.

inkl

Read news from The Economist, FT, and more,
with one subscription

3 Defensive Dividend Stocks to Scoop Up Now

3 Defensive Dividend Stocks to Scoop Up Now

Amid ongoing market uncertainty, Morgan Stanley believes these three defensive dividend-paying stocks could be ideal buys now.

AbbVie’s Call Action Suggests It Might Just Be a Buy

AbbVie’s Call Action Suggests It Might Just Be a Buy

Barchart.com’s Unusual Options Activity on Wednesday had 18 AbbVie call options in the Top 100. Not everyone believes it’s an excellent time to buy ABBV stock. Yesterday’s options market says otherwise.

1

Organisations

Johnson & Johnson (

Northrop Grumman

Public Service Enterprise

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Places

374,953 stories

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play